New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - amphotericin b 50mg (plus 2.5mg overage) - powder for injection - 50 mg - active: amphotericin b 50mg (plus 2.5mg overage) excipient: deoxycholic acid dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate

India - English - Central Drugs Standard Control Organization

cipla - amphotericin-b - inj - 50mg(amphotericin en capsulated in liposomes) - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

cephalon uk limited - amphotericin b - suspension for injection - 5 mg/ml

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - posaconazole - mycoses - antimycotics for systemic use - posaconazole accord is indicated for use in the treatment of the following fungal infections in adults:invasive aspergillosis;fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole accord is also indicated for prophylaxis of invasive fungal infections in the following patients: patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - posaconazole - mycoses - antimycotics for systemic use - posaconazole ahcl oral suspension is indicated for use in the treatment of the following fungal infections in adults:invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole ahcl oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; chlamydophilia felis inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 p; chlamydophilia felis inactivated vaccine-viral active 0.0 p; feline panleucopenia virus - inactivated vaccine-viral active 0.0 p; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 p; amphotericin antibiotic other 1.36 ug/ml; neomycin antibiotic other 12.0 ug/ml; polymyxin b antibiotic other 20.0 iu/ml; thiomersal mercury other 68.0 ug/ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline chlamydia psittaci | feline enteritis | feline rhinotracheitis | vaccine | calicivirus (feline) | enteritis (feline) | equine rotavirus | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 ml; feline panleucopenia virus - inactivated vaccine-viral active 0.0 ml; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 ml; amphotericin antibiotic other 0.0 ml; neomycin antibiotic other 0.0 ml; polymyxin b antibiotic other 0.0 ml; thiomersal mercury other 0.0 ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline enteritis | feline rhinotracheitis | calicivirus (feline) | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)